Table 1.
IC50 values for palbociclib, abemaciclib, and everolimus for wild-type and palbociclib-resistant sublines
| Cell line | Molecular-targeted agents | |||||
|---|---|---|---|---|---|---|
| Palbociclib | Abemaciclib | Everolimus | ||||
| IC50 (μM)a | RR ratiob | IC50 (μM)a | RR ratiob | IC50 (nM)a | RR ratiob | |
| MCF7 | 3.60 ± 0.20 | – | 0.36 ± 0.10 | – | 0.35 ± 0.10 | – |
| MCF7-P1 | 7.50 ± 1.80 | 2.10 | 0.78 ± 0.20 | 2.20 | 0.40 ± 0.10 | 1.10 |
| MCF7-P2 | 12.00 ± 2.40 | 3.30 | 2.77 ± 0.50 | 7.70 | 0.35 ± 0.20 | 1.00 |
| T47D | 1.70 ± 1.30 | – | 0.21 ± 0.10 | – | 4.19 ± 2.50 | – |
| T47D-PR | 13.50 ± 0.30 | 7.90 | 13.60 ± 1.40 | 64.80 | 0.74 ± 0.30 | 0.20 |
IC50 half-maximal inhibitory concentration
aMean ± standard deviation
bRelative resistance ratio = IC50 of palbociclib-resistant cells/IC50 of wild-type cells